BC
PRVB

Bridgefront Capital’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Bridgefront Capital’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-12,725
Closed -$107K – 730
2021
Q2 		$107K Buy
+12,725
New +$103K 0.04% 550

Other funds holding PRVB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
DCM
DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return

Bridgefront Capital's PRVB Position: Q3 2021 in Review

Bridgefront Capital sold out of Provention Bio, Inc. Common Stock (PRVB) in Q3 2021, closing a stake of 12,725 shares — an estimated $107K sold.

Bridgefront Capital first reported a position in PRVB in Q2 2021 and held it in 1 quarter. The position peaked at $107K in Q2 2021. 115 funds tracked by Wall St. Rank hold PRVB as of Q3 2021.

  • Bridgefront Capital reported no remaining Provention Bio, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Bridgefront Capital sold 12,725 Provention Bio, Inc. Common Stock shares in Q3 2021, an estimated $107K.
  • Bridgefront Capital first reported a position in Provention Bio, Inc. Common Stock in Q2 2021 and held it in 1 quarter.
  • Bridgefront Capital's Provention Bio, Inc. Common Stock position peaked at $107K in Q2 2021.
  • 115 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q3 2021.

Based on Bridgefront Capital's 13F filing for Q3 2021, filed 12 Nov 2021.